A Closet Full of Shoes

Shoes keep us warm, dry, active, and sometimes fashionable. Shoes are important for walking and traveling, to see and experience the world around us. I have fond memories of shoe shopping with my mom. Searching for a popular new style of boots for fall and winter, strappy sandals for spring and summer, or the perfect pair of high-heeled shoes that match a formal dress for a special occasion. There were many times we would laugh in the shoe department when we turned to each other with a shoe in hand—"Do you like this one?"—and we were holding up the same [...]

2024-03-08T11:02:30-05:00June 23, 2023|

The Power of Music

A few years ago, when I first heard country artist Jay Allen's song, "Blank Stares," it struck a chord with me. Every word explained exactly how I was feeling and what I was experiencing caring for my mother living with Alzheimer's disease. The song even begins with a snippet of a voicemail message that his mother left him. I, too, keep voicemail messages that my mom left for me and listen to them just to hear her voice. Jay shares his emotional story often in an effort to educate the public about this horrific disease without a cure. Jay released [...]

2024-03-08T11:23:31-05:00September 19, 2022|

You’ll Be in My Heart

Written by Stephanie Fisch, Director of Public Relations and Community Education. I recently attended a concert benefitting Penn Memory Center for continued dementia research at the Newtown Theatre with Jerry, Donna, and Kathleen, where the Phil Collins tribute band, Hello I Must Be Going put on a stellar performance. Betsy Szamboti and the team at Artis Senior Living of Yardley organized a very successful event, and I found it inspiring to be in a room full of people working toward a common goal to end Alzheimer’s for future generations. We value our partnerships with both Artis Senior Living of Yardley [...]

2024-03-08T11:25:36-05:00August 19, 2022|

I Wish You Could See Me Now

A letter to Lois Cohen, friend and family to Rothkoff Law Group, written by her grandson, Jared Fisch. Hi Bubbie, It’s me, Jared, your second of four grandsons. You'd be amazed by how tall Cameron and Jake have gotten. Jason started his first full-time job about two years ago, and now I graduated from college last month. There's so much to tell you about. I know you didn't have the opportunity to attend university and would have loved to live vicariously through me. I moved halfway across the country to attend the world's first and best journalism school at the [...]

2024-03-08T11:28:08-05:00July 8, 2022|

Dementia Care: Finding the Resources You Need

Finding quality dementia care is an important concern for countless families —and something we handle a lot with our clients at Rothkoff Law Group. The news recently reported Bruce Willis—an actor needing no further introduction—is stepping back from acting because he suffers from aphasia. Speculation furthered that he is suffering from cognitive impairment or dementia. This news felt oddly personal. I grew up watching Bruce in Die Hard, Die Hard II, as well as the other installments, along with countless other films of his. Beyond the personal effect, it also illustrates the hard truth that age-related illness, like dementia, knows [...]

2024-03-08T11:28:46-05:00June 3, 2022|

Aduhelm Coverage: Medicare’s Decision for the New Alzheimer’s Drug

On January 11, 2022, the Centers for Medicare and Medicaid Services (CMS) proposed that Medicare would offer Aduhelm coverage. Aduhelm is a drug for the treatment of mild Alzheimer’s disease, only as part of a clinical trial approved by CMS or supported by the National Institutes of Health (NIH). The trial will help to generate the evidence that CMS suggests is currently lacking regarding whether Aduhelm is reasonable and necessary for the treatment of Alzheimer’s disease. This preliminary National Coverage Determination (NCD) comes after months of handwringing over the potential impact of this new high-priced drug on Medicare spending and [...]

2024-03-08T12:10:31-05:00January 28, 2022|

Philadelphia Walk to End Alzheimer’s

We invite you to join our team, Love 4 Lois, for the Philadelphia Walk to End Alzheimer’s on Saturday, November 13, 2021, at Citizens Bank Park in Philadelphia, PA. Every year, thousands of Americans lace up for the Alzheimer’s Association Walk to End Alzheimer’s—the world’s largest fundraiser for Alzheimer’s care, support, and research. Since 2018, our team has been walking in honor of my mother, Lois, Rothkoff Law Group’s dear friend, and former co-worker, who is living with this disease. On October 21, 2021, Dr. Jason Karlawish—Professor of Medicine, Medical Ethics & Health Policy, and Neurology at the University of [...]

2024-03-08T12:13:35-05:00November 8, 2021|

Join Our Team: Love 4 Lois

One in 10 people over the age of 65 has Alzheimer’s dementia. Since the disease has affected a beloved former employee, Lois Cohen, we’ve been walking to end Alzheimer’s every November—and this year, we want you to walk with us. Learn how you can join our team and make a donation: http://bit.ly/love4lois2021

2024-03-08T12:17:55-05:00September 23, 2021|

Walk to End Alzheimer’s: Love for Lois

Every year, thousands of Americans lace up for the Alzheimer’s Association Walk to End Alzheimer’s—the world’s largest fundraiser for Alzheimer’s care, support, and research. And every year, our team walks for our dear friend and former co-worker Lois, who is living with this disease. Lois’s grandson, Jared Fisch, pens an anecdotal essay on what it looks like to be on the other end of Alzheimer’s watching a loved one change before you. Read on below and join the Rothkoff Law Group – Love for Lois team in the Walk to End Alzheimer’s. She’s Not Who She Used to Be I [...]

2024-03-08T12:19:11-05:00August 26, 2021|

FDA Approves New Alzheimer’s Drug

On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab), a new Alzheimer’s drug for the treatment of the disease. Aduhelm was approved using the “accelerated approval pathway,” which can be used for a drug for a serious or life-threatening illness that provides a therapeutic advantage over existing treatment. According to the FDA, “accelerated approval can be based on the drug’s effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with a required post-approval trial to verify that the drug provides the expected clinical benefit.” Was the approval of [...]

2024-03-08T12:25:48-05:00July 1, 2021|
Go to Top